Search Results for: Pharma: Clinical Roundup
-
Clinic Roundup
Meritage Pharma Inc., of San Diego, said a Phase IIb trial of oral budesonide suspension for eosinophilic esophagitis met its primary endpoin...The proposed revision would permit participants to receive either docetaxel re-treatment or cabazitaxel as chemotherapy in the clinical studyBioWorld Today | Wednesday, May 11, 2011 -
Financings Roundup
A.P. Pharma Inc., of Redwood City, Calif., will raise $4.5 million in convertible notes in a private placement deal with certain investors, including Tang Capital Partners...The discussion topics included dosing system, clarification of assays for manufacture and quality control, and a QT/metabolism clinical studyBioWorld Today | Tuesday, April 26, 2011 -
Merrimack Pharmaceuticals' Series G Brings in $77M
Under the agreement, GTC would receive an initial inventory of bulk drug substance for use in clinical studies...Merrimack's first major pharma deal, in 2009, focused on MM-121By Catherine Shaffer | BioWorld Today | Monday, April 18, 2011 -
Public Offering to Net a Cool $40M for ArQule
The two companies share equally the cost of Phase II and Phase III clinical studies...ArQule's clinical pipeline additionally includes ARQ 621, an Eg5 inhibitor, in Phase I and ARQ 736, a pan-RAF inhibitorBy Catherine Shaffer | BioWorld Today | Friday, January 21, 2011 -
NovImmune Tops Off Licensing Deal with $20.6 M
Clinical studies are slated to start in early 2011By Catherine Shaffer | BioWorld Today | Monday, December 20, 2010 -
XenoPort Prices Public Offering of 4M Shares
The Horizant NDA resubmission also included a final safety update, which provided updated and new safety information on patients in clinical studies who have been treated with the drug...Geron said it plans to use the net proceeds for R&D, including clinical trials for its product candidates, development activities for in-licensed products and other general corporate purposesBy Donna Young | BioWorld Today | Friday, December 10, 2010 -
Clinic Roundup
AstraZeneca plc, of London, and Bristol-Myers Squibb Co., of New York, reported results from a randomized, double blind Phase III clinical study demonstrating that the addition of the investigational drug dapagliflozin to existing therapy with glimepiride, a sulphonylurea, produced significant reductions of HbA1c levels, less than 7 percent, in adults with Type II diabetes vs...Sanofi and its partner, Zealand Pharma AS, of Copenhagen, Denmark, had reported top-line results in AprilBioWorld Today | Tuesday, September 21, 2010 -
Clinic Roundup
Clinical studies to date have shown a nasal formulation of a monovalent norovirus VLP vaccine to be immunogenic, having the ability to create an immune response, for example, and it is generally well toleratedBioWorld Today | Friday, September 17, 2010 -
Clinic Roundup
Bionomics Ltd., of Adelaide, Australia, released data that demonstrated efficacy of anti-anxiety compound BNC210 in preclinical and clinical studies...Bionor Pharma ASA, of Skein, Norway, reported that immune memory in HIV vaccination can be safely reactivated seven years after immunization with Vacc-4x, a peptide-based, therapeutic HIV vaccine, by re-vaccinating with Vacc-4xBioWorld Today | Tuesday, August 31, 2010 -
Clinic Roundup
Cerulean Pharma Inc., of Cambridge, Mass., reported results of a Phase I clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and preclinical data on Cerulean's development candidate, CRLX288, at the American Chemical Society National Meeting & Exposition, ongoing in BostonBioWorld Today | Friday, August 27, 2010 -
CeNeRx Hits Phase II Home Stretch with $13M Series C
Proceeds will be used for manufacture and clinical studies of its cancer therapeutic AEOL 10150, as well as preclinical development of other Aeolus compounds...Bioniche Pharma's lead product Urocidin for bladder cancer is currently in clinical trials. (See BioWorld Today, July 16, 2010.)By Catherine Shaffer | BioWorld Today | Monday, August 16, 2010 -
Dicerna Raises $25M Series B to Fund RNAi Cancer Program
Going forward, Dicerna will use the $25 million Series B financing to support clinical studies of its oncology therapeutics, and will rely on further nondilutive funding from pharma partners to develop and mature its technologyBy Catherine Shaffer | BioWorld Today | Thursday, August 12, 2010 -
Clinic Roundup
Antisense Pharma GmbH, of Regensburg, Germany, said the FDA issued an investigational new drug authorization for clinical studies with the transforming growth factor-beta 2 inhibitor trabedersen for patients with high-grade gliomaBioWorld Today | Wednesday, August 4, 2010 -
Sunesis' $28.5M Stock Sale to Fund Voreloxin Phase III Trial
The proceeds from the transaction will be used for further development of the company's lead clinical programs, including its Phase II clinical study program of Serdaxin, Zoraxel and ArchexinBy Catherine Hollingsworth | BioWorld Today | Friday, July 2, 2010 -
Clinic Roundup
Horizon Pharma Inc., of Northbrook, Ill., reported interim results from a pilot clinical study showing that Lodotra (modified-release prednisone tablet) chronotherapy might improve asthma control and asthma-related quality of life when added to standard asthma therapy in patients with severe nocturnal asthmaBioWorld Today | Thursday, May 20, 2010 -
ATS Roundup
KaloBios Pharmaceuticals Inc., of South San Francisco, said data from the initial clinical studies of KB001, an antibody fragment against PcrV on Pseudomonas aeruginosa, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosisBioWorld Today | Tuesday, May 18, 2010 -
Clinic Roundup
A Phase Ib study is planned at the established maximum-tolerated dose of 275 mg/m2 at various dosing schedules and in select tumor types including gastric, head and neck, breast and liver cancers, to seek additional signals of activity and to help guide future clinical studies...Noxxon Pharma AG, of Berlin, said it has successfully completed a Phase I trial with Spiegelmer NOX-A12, which is being developed for acute as well as chronic indications in the area of hematological malignancies and/orBioWorld Today | Tuesday, May 4, 2010 -
Clinic Roundup
Icagen Inc., of Research Triangle Park, N.C., said that based on the efficacy demonstrated in the firm's recent study of photosensitive epilepsy patients, coupled with a favorable clinical safety profile, consistent pharmacokinetics and the lack of a maximal tolerated dose in all clinical studies to date, the firm proposed, and the FDA has approved, a study of up to two additional cohorts of photosensitive epilepsy patients at higher doses of ICA-105665...Icagen said it currently expects that theBioWorld Today | Wednesday, April 28, 2010 -
Adocia Raises $20M to Boost Protein Chaperone Technology
We have established collaborations with two big pharma companies on that," Soula said...The company said that funding will allow it to accelerate global launch of lead product ViaMetrics-E, a rapid, noninvasive procedure designed to enhance in vitro fertilization outcomes, as well as to complete an ongoing FDA clinical study and implement manufacturing and product enhancementsBy Staff Reports | BioWorld Today | Wednesday, January 13, 2010 -
Clinic Roundup
AM-Pharma BV, of Bunnik, the Netherlands, reported positive results from its Phase II acute kidney injury trial with alkaline phosphatase, which showed statistically significant improvement on the primary clinical endpoint and on several secondary endpoints after interim analysis of the treatment effect on 26 patients...This is the fifth clinical study to be initiated on STA-9090, a synthetic, small molecule Hsp90 inhibitor with a novel chemical structureBioWorld Today | Friday, December 18, 2009
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.